2020 ASCO Virtual Direct™ Highlights
2020 ASCO Updates on R/M ACC & Tumors With HRAS Mutations: Axitinib vs. Observation - What Are the PFS/OS Rates? What Does the Genomic Analysis Suggest? Is FTase Inhibitor Tipifarnib Safe?
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Emrullah Yilmaz
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Emrullah Yilmaz
Comments 0
Login to view comments.
Click here to Login
